Warning: Creating default object from empty value in /home/customer/www/molecularsynthetics.com/public_html/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/slideshow_layerslider/slideshow_layerslider.php on line 28
Executive Summary - Molecular Synthetics

Positron Energy Generation System Executive Summary

This opportunity provides an investor with a chance to participate in one of the truly revolutionary and transforming technologies of the century — the advent of matter-antimatter reactions as a routine power source.

This technology can replace all carbon fuels, solar, hydro, geothermal and wind, utterly transforming the technological basis of energy sources across the planet. The necessary technology is available for rapid implementation although a high intensity period of development over the next 360 days will be required at an expense of five million dollars.

The inventor and CEO, Aaron G. Filler, MD, PhD, has created some of the most important technologies in use today — with licenses to siemens, GE and Philips (from NeuroGrafix, of which Dr. Filler is also CEO). The positron provisional patent application, filed July 21, 2014, and to be assigned to Molecular Synthetics, is the basis of a potential future trillion-dollar renewed industrial base.

At one level, there are positron-based energy storage battery systems, at the next level active power generation to drive major machinery, and at the highest level, a previously unexplored positron-electron annihilation chain reaction that can be readily kindled and controlled for nearly unlimited carbon-free production of electricity in any environment on earth or in space, day or night, in a fixed facility or in a moving vehicle.

One part of the underlying technology was invented by Dr. Filler more than 20 years ago, but its application for energy generation was not possible wihtouto the further inventions described in the July 21, 2014, provisional patent filing. The original company to which the predecessor patent was assigned — SynGenix / Sirus Pharma — held investment from Hermann Hauser, one of the leading venture capitalists in Europe as well as venture investments from Lloyds Bank an d was sold to Arakis in 2003, but the positron patent was then assigned to Molecular Synthetics.

In positron emission tomography (PET imaging), the technology relies on production fo short half-life positron emitters, often by use of a hospital-owned cyclotron — these are now small enough to be operated by power from a solar array. The positron emitter disintegrates releasing a positron — an antimatter electron. It travels through tissue losing energy until, at rest, it fuses with an electron in a matter-antimatter reaction that releases two high-energy photons (511 keV – kilo electron volts) traveling in opposite directions. In a PET scanner, we detect the simultaneous arrival of the two photos, draw a line between the two detector elements, and know that the annihilation occurred along that line.

The promise of high-resolution imaging is undecut, however, because the positron travels up to a centimeter before it loses enough energy to be at rest and under annihilation. In the original invention 20 years ago, Dr. Filler showed that the distance of travel of the positron was related to the density of the medium through which it traveled, so that if we put manganese-52 inside a ferrite spinel nanoparticle — the distance of travel before annhilation was reduced mroe than 80% and the spatial resolution of PET was greatly improved.

In the new invention, Dr. Filler exploits the high energy photons for photovoltaic energy production. Firstly, a solar photon is near 1 eV and it takes abou tthree of these to make one electron (33% efficiency). However, the matter-antimatter annihilation photons are each 511 keV so there is the potential for a million interactions from each annihilation. This results first in a battery since we can use solar energy to drive the cyclotron to make the positron emitter. The nanoparticles are stably solvated in liquid such as water so it is a portable, pourable high-density source of photons for electricity generation.

More importantly, in this work Dr. Filler has now seen that it appears to be possible to initiate a positron chain reaction — a new phenomenon covered in the patent application. This occurs because we can increase the energy of the photons by accelerating the positrons and electrons in charged fields to add this energy to their rest energies before the annihilation event. When they interact, the photons have th eadditional energy applied by the high voltage electrodes. Then, the photons can cause pair production in interactions with electrons in which new positrons are generated. With this step, the original foil is more or less just “kindling” and we use the fuel of the substance of the superparamagnetic ferrite spinel nanocrystals to take the hits from the energetic photons and continue generating new positrons — each capable of causing several hundred thousand photovoltaic events.

Additional technology advance is devoted to the previously unresolved problem of capturing electrons from high energy photons as they undergo Compton and photoelectric interactions with matter as they lose energy toward a low energy required for existing photovoltaic cells. In this fashions, each disintegration is induced to generate many millions of electrons on a sustained basis. Systems are provided in the patent application for taking advantage of the generation of the photons throughout the interior of a motor or conversion device rather than having to capture from the sun’s rays as in the (soon to be archaic and obsolete) solar model.

This is an early-stage project but one that can come to market very rapidly over a one- to two-year time frame. It will also grow spectacularly in value as technical milestones are reached. There will be tremendous attention focused on a non-carbon technology with a liquid pourable fuel capable of replacing fossil fuel, carbon, solar and wind. The risks arise in successful confirmation of the key points of the technology: (1) Electricity extraction from the high-energy photons; (2) Establishment of the positron chain reactions. Although other parts of the technology — (3) Positron Battery — are only matters of the rate at which efficiency of energy production is improved — (4) Scale up to industrial magnitude is another risk issue. Because the patent itself is at the earliest stage — (5) Patent grant issues such as unknown prior art are concerns, however given the extraordinary attention and interest this technology is likely to generate, a strategy of filing a provisional patent application, funding and racing to the one-year deadline to file a final patent, and then seeking additional funding to build an industrial power house or extensively license the technology are entirely appropriate to this profoundly important area of technology advance.

Molecular Synthetics seeks $5 million for a 5% ownership share in the company in order to undertake and complete the radiation-shielded laboratory work over the next 360 days in advance of the final patent filing. This is a “fire of Prometheus” event that has the potential to unleash a vast new world of technologies. Molecular Synthetics must rush to take the lead in generating new technology and new intellectual property rights in this new field that promises to replace and revise much of the energy component of the world’s industrial and commercial base.

Preliminary Positron Provisional Patent Filing – Patent Pending

This Executive Summary may contain forward looking statements. Reasonable expectation of significant growth is not an absolute assurance that such growth will in fact take place. This Executive Summary is intended for qualified experienced investors. Molecular Synthetics has taken all reasonable care to ensure that the facts stated in this document are true and accurate in all material respects, and that there are no other material facts the omission of which would make misleading any statement in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance, or guarantee that those assumptions are correct or exhaustive. Accordingly, neither Molecular Synthetics nor any of its agents shall be liable for any direct, indirect or consequential loss or damage suffered by any person relying on any statements in or omission from this document and any such liability is expressly excluded.